In October, Eli Lilly announced a strategic investment exceeding $1 billion to bolster its manufacturing footprint in India, targeting the rapidly growing diabetes and obesity markets. The company plans to partner with local contract manufacturers specializing in complex biologics, vials, and injectables, rather than building a wholly owned facility. This move marks Lilly’s first major manufacturing initiative in India and aims to secure supply chains for key therapies such as Mounjaro and Zepbound, supporting anticipated volume growth of 30%–40% annually in the region over the next five years.

Eli Lilly recently submitted a New Drug Application for orforglipron, its once-daily oral GLP-1 agonist for obesity and type 2 diabetes. Phase 3 trials showed sustained weight loss of up to 15% over 52 weeks, with favorable safety and tolerability profiles. The candidate received a Priority Review voucher, shortening the U.S. FDA evaluation window to as little as two months. Approval early next year would position Lilly to capture patients preferring pills over injectables, potentially expanding its addressable market by an estimated 25%–30%.

According to the latest 13F filings, several major funds have rebalanced their positions in Eli Lilly. Burney Co. reduced its holding by 1.9% to 28 069 shares, valued at $21.42 million. In contrast, Lazard Frères Gestion increased its stake by 114.3% to 77 295 shares, and Central Pacific Bank Trust Division added 1 843 shares (a 25.8% rise) to reach 8 990 shares. These shifts reflect growing confidence among some managers in Lilly’s pipeline execution and dividend growth prospects, while others have taken profits after a year-to-date share gain exceeding 25%.